Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

Rhea-AI Summary

Corvus Pharmaceuticals (Nasdaq: CRVS) will host a conference call and webcast on May 8, 2023, at 4:30 PM ET to discuss a business update and report first quarter 2023 financial results. Investors can join the call by dialing 1-844-825-9789 (U.S.) or 1-412-317-5180 (international) and using passcode 2096044. A live webcast will also be available through the investor relations section on the Corvus website.

Corvus Pharmaceuticals is focused on developing novel therapies for cancer. Its lead candidate, CPI-818, is in a Phase 1/1b trial aimed at T cell lymphomas, while two additional programs, CPI-444 and CPI-006, are also in various stages of clinical trials. The company continues to advance its innovative pipeline in the biopharma sector.

Positive

• Upcoming conference call may provide key updates on business and financial performance.
• Lead product candidate CPI-818 is currently in Phase 1/1b trials, indicating progress in cancer treatment development.
• Diverse pipeline with multiple clinical programs under development.

Negative

• None.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on May 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2023 financial results.

The conference call can be accessed by dialing 1-844-825-9789 or 1-412-317-5180 (international) or by clicking on this link and requesting a return call and using the conference passcode 2096044. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T cell lymphomas. The Company’s second clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor that is in an open-label Phase 1b/2 clinical trial. Its third clinical program, mupadolimab (CPI-006), is a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com  

FAQ

When will Corvus Pharmaceuticals report its first quarter 2023 financial results?

Corvus Pharmaceuticals will report its first quarter 2023 financial results on May 8, 2023.

What is the ticker symbol for Corvus Pharmaceuticals?

The ticker symbol for Corvus Pharmaceuticals is CRVS.

How can investors participate in the Corvus Pharmaceuticals conference call?

Investors can participate in the conference call by dialing 1-844-825-9789 (U.S.) or 1-412-317-5180 (international) and using passcode 2096044.

What are the main products being developed by Corvus Pharmaceuticals?

Corvus Pharmaceuticals is developing CPI-818 for T cell lymphomas, CPI-444 as an A2A receptor inhibitor, and CPI-006 as a CD73-directed monoclonal antibody.